Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Genome sequencing of global IMP- and VIM-producing Enterobacteriaceae

PROVIDER: PRJDB6678 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR065573_1.fastq.gz	Fastqsanger.gz
	DRR065573_2.fastq.gz	Fastqsanger.gz
	DRR065574_1.fastq.gz	Fastqsanger.gz
	DRR065574_2.fastq.gz	Fastqsanger.gz
	DRR065575_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 282

Similar Datasets

Enterobacteriaceae

Project description:IMP- and VIM-producing Enterobacteriaceae

| PRJDB4948 | ENA

First dataset - bacterial proteome of carbapanemase-producing Escherichia coli and other Enterobacteriaceae under antibiotic pressure

Project description:Antibiotic resistance associated with the expression of the clinically significant carbapenemases, IMP, KPC, and NDM and OXA-48 in Enterobacteriaceae is emerging as a worldwide calamity to health care. In Australia, IMP-producing Enterobacteriaceae is the most prevalent carbapenemase-producing Enterobacteriaceae (CPE). Genomic characteristics of such carbapenemase-producing Enterobacteriaceae (CPE) are well described, but the corresponding proteome is poorly characterised. We have thus developed a method to analyse dynamic changes in the proteome of CPE under antibiotic pressure. Specifically, we have investigated the effect of meropenem at sub-lethal concentrations to develop a better understanding of how antibiotic pressure leads to resistance. Escherichia coli, producing either NDM, IMP or KPC type carbapenemase were included in this study, and their proteomes were analysed in growth conditions with or without meropenem.

2018-07-11 | PXD008019 | Pride

PAE

Project description:Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high risk-clones ST175 and ST244 producing VIM-2, VIM-1, IMP-8, VIM-20 and KPC-2

| PRJEB31466 | ENA

Enterobacteriaceae

Project description:Clinical and molecular analyses of bloodstream infections caused by IMP producing Enterobacteriaceae

| PRJDB7154 | ENA

Enterobacter

Project description:Enterobacter strains Coproducing IMP-34 and VIM-1

| PRJNA476055 | ENA

IMP-producing Pseudomonas aeruginosa

Project description:IMP-producing Pseudomonas aeruginosa

| PRJEB53622 | ENA

Project description:VIM-producing Atlantibacter hermannii

| PRJNA692183 | ENA

Project description:Carbapenemase-producing Enterobacteriaceae sequencing

| PRJNA1187236 | ENA

Pseudomonas aeruginosa

Project description:IMP-13 producing Pseudomonas aeruginosa

| PRJNA1106512 | ENA

The microbial metabolite imidazole propionate modulates hypothalamic activity and stress-induced behaviors

Project description:Neural circuits driving mammalian behaviors are highly plastic and modulated by internal and external factors, including the gut microbiome. We identify imidazole propionate (ImP), a microbial metabolite linked to metabolic disorders, as a key modulator of brain activity and behavior. Bacterially derived ImP enters the systemic circulation and brain, where it alters neuronal gene expression and activity in the hypothalamus without inducing overt neuroinflammation. Elevating systemic ImP promotes stress-related pathways and disrupts GABAergic/glutamatergic signaling in the hypothalamus before peripheral glucose dysregulation occurs. Similarly, colonization with the ImP-producing bacterium Eggerthella lenta elevates behavioral and molecular features of stress. In a mouse model of type 2 diabetes, the gut microbiome exhibits an enhanced ability to produce ImP, leading to elevated systemic levels that are associated with heightened stress responses. In humans, higher ImP associates with reduced hypothalamic reactivity to food cues, impaired stress-coping, and increased emotional eating, mirroring the causal links between ImP, hypothalamic activity, and stress-related behaviors in mice. Overall, these findings establish ImP as a notable microbial metabolite that links gut dysbiosis to altered hypothalamic function and stress in metabolic disease.

2025-06-26 | GSE300937 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data